Related Experiment Video
Updated: Aug 6, 2026

Tropomodulin 3 Overexpression as a Marker for Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Foundation Model-empowered Multimodal Prediction of Platinum Resistance in High-grade Serous Ovarian Cancer: A
Qiu Bi1, Linhao Qu2, Yang Liu3
1Department of MRI, the First People's Hospital of Yunnan Province, the Affiliated Hospital of Kunming University of Science and Technology, Kunming, Yunnan 650032, China (Q.B., J.Y., L.W.).
Rationale And Objectives:
To develop and validate a foundation model (FM)-empowered multimodal framework to predict platinum resistance in patients with high-grade serous ovarian cancer (HGSOC).
Materials And Methods:
This multicenter retrospective cohort study included 744 HGSOC patients who underwent primary debulking surgery across four centers. Perioperative multimodal data were collected, including clinical variables, preoperative pelvic magnetic resonance imaging (MRI), and postoperative hematoxylin and eosin (H&E)-stained whole slide images (WSIs). Pretrained radiology and pathology FMs were used as frozen feature extractors, and attention-based aggregation was applied to summarize variable-length MRI slices and WSI tiles. A cross-modal fusion module integrated modalities and supported missing-modality inference. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC) and compared with late-fusion (LF) baselines.
Results:
In the internal validation cohort, unimodal and multimodal FM variants achieved AUCs ranging from 0.708 to 0.780, and in external test cohorts A, B, and C achieved AUCs ranging from 0.653 to 0.790. The trimodal FM (clinical+MRI+WSI) achieved the highest AUC in all cohorts (internal validation: 0.780; external cohorts A, B, and C: 0.779, 0.781, and 0.790, respectively), outperforming the trimodal LF model (internal validation: 0.753; external cohorts A, B, and C: 0.729, 0.715, and 0.730, respectively).
Conclusion:
A FM-empowered multimodal model integrating clinical, MRI, and pathological data was constructed to predict platinum resistance in HGSOC, demonstrating superior and stable performance across centers.
Related Concept Videos
Treatment Resistent Cancers
Treatment Resistant Cancers
